354 Index Name Paper ref. Name Paper ref. Morisset, S Wed 051 Morita, H Thu 038 Morita, K Mon 303 Morita, S Wed 414 Moritani, T Wed 422, Wed 415 Mørk, A FC17.4.2 Moro, C Tue 199 Moro, N Wed 263, Tue 214 Moroni, S Mon 003, Wed 003 Morris, B FC17.1.4 Morris, R Mon 102, Tue 495 Morrow, L Mon 175 Morvay, N Tue 157 Moscatelli, G Mon 003, Wed 003 Mosekilde, E FC07.1.1 Moseley, E Tue 002 Moshfegh, A Mon 055 Moshkov, AV Thu 238 Mosquera, B Tue 348 Moss, E Wed 132 Mostefai, HA Wed 196 Motamedi, R Thu 309, Tue 469 Motau, Harold Tue 003 Motavallian Naeini, A YI.07 Motegi, T Mon 440 Motevalian, M Thu 006 Motomura, S Tue 430 Motosugi, Y Thu 268 Motsoaole, M Thu 315 Möttönen, T FC09.2.5 Mou, Y Tue 155 Mouly, S Tue 188, Tue 189, Wed 191, FC01.4.4 Moura, D Wed 114 Moura, D Tue 123 Moura, E Wed 114, Thu 398 Mousavi, SH Thu 313, Thu 342, Tue 424 Moustafin, IG Thu 096 Moutin, E FC11.3.3 Mozhaeva, T Tue 150 Mpamhanga, CP Tue 479 Mpindi, J-P Tue 436 Mrhar, A FC07.3.5 Mrsic Pelcic, J Tue 095 Mu, X Tue 307, Thu 314 Muceniece, R Thu 189, Wed 045 Mudzviti, T Tue 004 Mülders, V Tue 108 Müller, C Thu 018 Müller, CE Tue 238 Müller, M Thu 438 Müller, S Wed 119 Mueller, SC Tue 115 Mürdter, T Wed 133 Mugabo, P Thu 315 Mugelli, A Thu 302, Tue 093 Mugosa, S Tue 098, Wed 135, Wed 134 Muguruza, C Thu 399 Muhamedzhanova, G Tue 079 Mukonzo, JK Tue 005, Wed 136 Muktar, H Wed 145 Mulabegovic, N Wed 199 Mulcahy, F Thu 442 Mulder, P Wed 196 Mulleman, D Tue 198 Mulvany, M Wed 375, Wed 240 Mulvany, M W17.1 Mulvany, MJ Thu 234, Mon 200 Munck, A Wed 160, FC13.1.5 Mungiu, O Mon 108, Tue 134 Munhoz, C Mon 292 Munk, S Thu 058 Muñoz, A Mon 123, Mon 254 Muñoz, R Mon 451 Muñoz-Marin, J Mon 206, Mon 278, Tue 144, Wed 215 Muntau, AC Wed 016, Thu 014 Muona, A W21.3 Muraguchi, M Thu 103 Murai, M Mon 402 Murakami, M Tue 236 Muramatsu, I W01.2.3, Thu 046 Muramatsu, M Wed 107, Thu 286 Murase, S-I Wed 060 Murat, N Tue 200 Murciano, C Tue 478, Tue 422 Murguia-Romero, M Tue 150 Murphy, SE FC17.4.3 Murphy-Ullrich, J Thu 251 Murugan, DD Thu 219 Musabegovic, J Wed 004, Wed 171 Musavi, P Mon 231 Musazzi, L Thu 400 Muscará, MN Wed 233 Muscatello, MR Thu 419 Musgrave, U FC16.3.7 Musil, P Mon 219 Musilek, K Tue 343, Mon 075, Tue 448 Mustafa, J Thu 057 Mustafa, MR Thu 219, Tue 254 Mustafa, R Wed 370 Mustata, C Thu 177, Thu 178, Mon 109 Mustonen, E Tue 166 Muthig, V W01.2.4 Mutka, A-L Mon 215 Mutlu, O Mon 387, Tue 145, Wed 351, Thu 401 Mwandingi, P Thu 315 Mwinyi, J Thu 435 Myllynen, P Mon 063, Mon 076 Myöhänen, TT Mon 444 Myronidou-Tzouveleki, M Tue 141 Myslivecek, J Thu 039 Mzah, D Mon 378 Nabeshima, T Thu 402 Nabipoor, I Tue 014 Nada, SA Tue 451 Naeini, KS Tue 369 Nafrialdi, Tue 009 Nagahama, H Mon 173 Nagai, H Tue 373 Nagano, M Thu 108 Nagano, M Thu 403 Nagashima, R Mon 461, Tue 375, Thu 099 Naggara, O Mon 191 Nagy, S Tue 414, Nahimi, A Thu 405, Thu 404 Naidoo, D Mon 478
Name Paper ref. Name Paper ref. Naidoo, M Tue 110 Naidoo, P Tue 110 Naidu, R Tue 254 Naim Abu Nabah, Y W09.4 Naina, MI Wed 137 Naito, T Tue 484, Tue 491 Najafi, E Thu 365 Najafi, M Tue 164 Najafian, B Mon 231 Najafzadeh, H Mon 222 Nakabeppu, Y Wed 141 Nakada, Y Tue 151 Nakae, Y Thu 013 Nakagawa, M FC03.2.5, Wed 138 Nakagawa, S Tue 225 Nakagawa, T Tue 055 Nakagiri, A Tue 236 Nakahara, T Wed 264 Nakahata, N Wed 373, Wed 078 Nakajima, K Thu 402 Nakamori, Y Tue 274 Nakamura, E W02.1.3, Thu 263 Nakamura, K Tue 067, Tue 143, Tue 167, Thu 040, Thu 263, Thu 320 Nakamura, M Mon 112 Nakamura, S Thu 220 Nakamura, T Tue 373 Nakamura, Y Mon 441 Nakanishi-Ueda, T Tue 443 Nakano, Y Tue 201, Thu 416 Nakarandake, E Wed 203, Mon 257 Nakashima, H Wed 127 Nakasone, J Thu 344 Nakatsu, K Tue 414 Nakayama, J Wed 115 Nakayama, K Thu 226, Thu 248, W09.4 Nakayama, KI W09.4 Nakazawa, M Tue 177 Nam, JH Tue 046, Mon 068 Nam, MH Thu 090 Namekata, I Tue 168, Thu 260 Namiki, N Tue 144 Namkung, Y Thu 063 Namour, F Tue 280 Namvaran, F Tue 485 Namvaran, MM Mon 088 Nanba, D Thu 406 Nancy, G Wed 219 Nanda, S Thu 410 Näpänkangas, J Tue 166 Narita, M Thu 188, Thu 188, Wed 065 Narum, S Wed 139 Narumiya, S Mon 194, Tue 260, Tue 294 Nasal, A Mon 197 Nascimento, E Mon 094, Mon 095, Mon 097 Nascimento, NRF Wed 297 Nascimento, TL Thu 351, Thu 352 Nashida, T Tue 060 Nashun, B Wed 039 Nasisi, A Thu 111 Näsman, J Wed 081, Thu 051 Nasser, A Mon 089 Nassif, A Tue 045, Tue 041 Nastos, S Tue 368 Nasu, Y Wed 373 Nasyrova, S Tue 079 Natvig, B Tue 143 Naulaers, G Wed 001 Navarra, Michele Thu 316, Thu 364 Navarrete-Vazquez, G Tue 149 Navarro, JM Tue 123 Navarro-Dorado, J Mon 206, Tue 144, Wed 215, Wed 228, Thu 264, Thu 240 Nawaratne, V Thu 041 Nayeri, K Tue 015 Naylor, C Wed 409 Nazer, D Tue 110 Nazifi, S Tue 015 Nazila, T Thu 181 Ndisang, JF Tue 124 Nechifor, M FC14.2.6, Mon 162, Thu 175 Neef, CK W29.4 Negoro, T Tue 201 Negredo, P Mon 079 Negrete, R Thu 042, Wed 059 Negura, T Tue 459 Nejime, N Tue 143, Tue 067 Nelissen, J Wed 287 Nelissen, Jelly Thu 221 Nelson, M Thu 279, YI.05 Nelson, MT FC08.3.3, FC15.2.4 Németh, J Tue 125, Tue 142 Nemethy, Z Wed 423 Nepote, V Tue 305 Nerobkova, L Mon 462 Nesi, M Thu 043 Nesi, RT Wed 342 Nesic, Z Mon 114 Neta, C Wed 140 Neu, E Mon 245, Mon 479, Tue 099, Tue 214, Thu 211, Thu 354 Neu, R Thu 354, Tue 099 Neubig, R YI.01, Thu 044, Tue 479, Thu 065 Neugebauer, W Wed 037 Neumann, J Tue 169 Neuvonen, PJ Mon 380, Tue 062, Thu 284, Tue 316, Tue 330 Neverauskas, V Tue 329 Neves, BM Mon 291 Neville, K FC13.3.5 Newall, DR W10.2 Newman, A Wed 126 Newman, AH FC02.3.5 Newman-Tancredi, A Thu 024 Nezic, D Thu 324 Nezic, L Tue 237 Neznamov, G Tue 024 Ng, ESK Tue 417, Wed 345 Ng, K-Y Thu 045 Ng, KFJ Thu 281 Ng, L Thu 393 Ng, PY Tue 252 Ng, WK Tue 452 Ngokpol, S Mon 355, Tue 006, Tue 007 Nguyen, CH Tue 180 Nguyen, D-T Mon 242 Nguyen, TMH Mon 263 Index 355
- Page 1:
of basic and clinical pharmacology
- Page 4 and 5:
Congress patron 2 HRH Crown Princes
- Page 6 and 7:
Congress President Kim Brøsen Secr
- Page 8 and 9:
General information Registration &
- Page 10 and 11:
Banks, currency & credit cards The
- Page 12 and 13:
Information to presenters ■ The a
- Page 14 and 15:
Hotel Bella Center Copenhagen Groun
- Page 16 and 17:
Programme at a glance Time Hall A2
- Page 18 and 19:
16 General events General events Op
- Page 20 and 21:
Programme outline Plenary lectures
- Page 22 and 23:
FC10 Drugs for half the world: Paed
- Page 24 and 25:
Tue 12:45 W13 Workshop: Novel perip
- Page 26 and 27:
W01 Pharmacology of adrenoceptors:
- Page 28 and 29:
W02 Symposium on advances in GI pha
- Page 30 and 31:
W04 Symposium: Antioxidants as ther
- Page 32 and 33:
Plenary lectures PL01 Plenary lectu
- Page 34 and 35:
FC02 Transmembrane transport: Persp
- Page 36 and 37:
FC04 Pharmacoepidemiology, current
- Page 38 and 39:
FC06 The heart gone wrong: Stabiliz
- Page 40 and 41:
FC09 Inflammation and immunopharmac
- Page 42 and 43:
W02 Symposium on advances in GI pha
- Page 44 and 45:
SS01 Sponsored symposium Sponsored
- Page 46 and 47:
W06 Workshop. Effect of disease on
- Page 48 and 49:
W08 Workshop. Identifying targets f
- Page 50 and 51:
W10 Workshop. Innovative Medicines
- Page 52 and 53:
FC01 Clinical pharmacology in the e
- Page 54 and 55:
FC03 Ion channels in analgesia and
- Page 56 and 57:
FC05 Translational science in the m
- Page 58 and 59:
FC06 The heart gone wrong: Stabiliz
- Page 60 and 61:
FC08 Development in the treatment o
- Page 62 and 63:
Plenary lectures PL04 Plenary lectu
- Page 64 and 65:
FC01 Clinical pharmacology in the e
- Page 66 and 67:
FC03 Ion channels in analgesia and
- Page 68 and 69:
FC05 Translational science in the m
- Page 70 and 71:
FC07 Simulation and data modelling
- Page 72 and 73:
FC09 Inflammation and immunopharmac
- Page 74 and 75:
W12 Workshop. Experimental pain met
- Page 76 and 77:
W14 Workshop. Translating the human
- Page 78 and 79:
W15 Workshop. The IUPHAR initiative
- Page 80 and 81:
W17 Workshop. Standards for PhD Edu
- Page 82 and 83:
W19 Workshop. Influence of degenera
- Page 84 and 85:
FC02 Transmembrane transport: Persp
- Page 86 and 87:
FC04 Pharmacoepidemiology, current
- Page 88 and 89:
FC06 The heart gone wrong: Stabiliz
- Page 90 and 91:
FC08 Development in the treatment o
- Page 92 and 93:
PL10 ASPET Plenary Lecture Chair: T
- Page 94 and 95:
FC10 Drugs for half the world: Paed
- Page 96 and 97:
FC12 Ion channelopathies: New windo
- Page 98 and 99:
FC14 Addiction and doping: Neurobio
- Page 100 and 101:
FC17 New approaches and targets in
- Page 102 and 103:
W04 Symposium: Antioxidants as ther
- Page 104 and 105:
W21 Workshop. Inflammation - here,
- Page 106 and 107:
W23 Workshop. Applying pharmacogeno
- Page 108 and 109:
W25 Workshop. High science in the l
- Page 110 and 111:
W27 Workshop. Approaches to medicin
- Page 112 and 113:
FC11 G protein-coupled 7TM receptor
- Page 114 and 115:
FC13 Maximising benefits and minimi
- Page 116 and 117:
FC15 Endothelium in Health and dise
- Page 118 and 119:
FC17 New approaches and targets in
- Page 120 and 121:
FC18 Nuclear receptor targets for t
- Page 122 and 123:
PL16 Plenary Lecture Supported by a
- Page 124 and 125:
FC11 G protein-coupled 7TM receptor
- Page 126 and 127:
FC13 Maximising benefits and minimi
- Page 128 and 129:
FC15 Endothelium in Health and dise
- Page 130 and 131:
FC17 New approaches and targets in
- Page 132 and 133:
W28 Workshop. The Boehringer-Ingelh
- Page 134 and 135:
W30 Workshop. Is eNOS still a valid
- Page 136 and 137:
W32 Workshop. The good, the bad and
- Page 138 and 139:
W34 Workshop. State-of-the-art of b
- Page 140 and 141:
FC10 Drugs for half the world: Pedi
- Page 142 and 143:
FC12 Ion channelopathies: New windo
- Page 144 and 145:
FC14 Addiction and doping: Neurobio
- Page 146 and 147:
FC16 Natural products: Past and fut
- Page 148 and 149:
FC18 Nuclear receptor targets for t
- Page 150 and 151:
PL22 Plenary Lecture Chair: Zhi-Bin
- Page 152 and 153:
FC11 G protein-coupled 7TM receptor
- Page 154 and 155:
FC13 Maximising benefits and minimi
- Page 156 and 157:
FC15 Endothelium in health and dise
- Page 158 and 159:
FC17 New approaches and targets in
- Page 160 and 161:
158
- Page 162 and 163:
FC01 Clinical pharmacology in the e
- Page 164 and 165:
FC01 Clinical pharmacology in the e
- Page 166 and 167:
FC02 Transmembrane transport: Persp
- Page 168 and 169:
FC03 Ion channels in analgesia and
- Page 170 and 171:
W12 Experimental pain methods in de
- Page 172 and 173:
FC04 Pharmacoepidemiology, current
- Page 174 and 175:
FC05 Translational science in the m
- Page 176 and 177:
FC05 Translational science in the m
- Page 178 and 179:
FC06 The heart gone wrong; stabiliz
- Page 180 and 181:
FC07 Simulation and data modelling
- Page 182 and 183:
FC08 Developments in the treatment
- Page 184 and 185:
FC09 Inflammation and immunopharmac
- Page 186 and 187:
FC09 Inflammation and immunopharmac
- Page 188 and 189:
FC09 Inflammation and immunopharmac
- Page 190 and 191:
FC13 Maximising benefits and minimi
- Page 192 and 193:
FC13 Maximising benefits and minimi
- Page 194 and 195:
W03 Targeting TRP channels for pain
- Page 196 and 197:
W19 Influence of degeneration and r
- Page 198 and 199:
W19 Influence of degeneration and r
- Page 200 and 201:
W20 Pharmacology education for a su
- Page 202 and 203:
FC01 Clinical pharmacology in the e
- Page 204 and 205:
FC02 Transmembrane transport: Persp
- Page 206 and 207:
FC02 Transmembrane transport: Persp
- Page 208 and 209:
FC04 Pharmacoepidemiology, current
- Page 210 and 211:
FC05 Translational science in the m
- Page 212 and 213:
FC05 Translational science in the m
- Page 214 and 215:
FC06 The heart gone wrong; stabiliz
- Page 216 and 217:
FC07 Simulation and data modelling
- Page 218 and 219:
FC08 Developments in the treatment
- Page 220 and 221:
FC09 Inflammation and immunopharmac
- Page 222 and 223:
FC09 Inflammation and immunopharmac
- Page 224 and 225:
FC09 Inflammation and immunopharmac
- Page 226 and 227:
FC13 Maximising benefits and minimi
- Page 228 and 229:
FC13 Maximising benefits and minimi
- Page 230 and 231:
FC19 General session Tue 361 Analge
- Page 232 and 233:
FC19 General session - Biologics Tu
- Page 234 and 235:
FC19 General session - Haematology
- Page 236 and 237:
FC19 General session - oncology Tue
- Page 238 and 239:
FC19 General session - oncology Tue
- Page 240 and 241:
FC19 General session - Toxicology T
- Page 242 and 243:
W02 Symposium on advances in GI pha
- Page 244 and 245:
W11 New opportunities in the pharma
- Page 246 and 247:
W23 Applying pharmacogenomics (PGX)
- Page 248 and 249:
FC10 Drugs for half the world: Paed
- Page 250 and 251:
FC11 G protein-coupled 7TM receptor
- Page 252 and 253:
FC11 G protein-coupled 7TM receptor
- Page 254 and 255:
FC12 Ion channelopathies: New windo
- Page 256 and 257:
FC13 Maximising benefits and minimi
- Page 258 and 259:
FC13 Maximising benefits and minimi
- Page 260 and 261:
FC14 Addiction and doping: Neurobio
- Page 262 and 263:
FC15 Endothelium in health and dise
- Page 264 and 265:
FC15 Endothelium in health and dise
- Page 266 and 267:
FC15 Endothelium in health and dise
- Page 268 and 269:
W30 Is eNOS Still a valid therapeut
- Page 270 and 271:
FC16 Natural products: Past and fut
- Page 272 and 273:
FC16 Natural products: Past and fut
- Page 274 and 275:
FC16 Natural products: Past and fut
- Page 276 and 277:
FC17 New approaches and targets in
- Page 278 and 279:
FC17 New approaches and targets in
- Page 280 and 281:
W34 State-of-the-art of basic and c
- Page 282 and 283:
FC10 Drugs for half the world: Paed
- Page 284 and 285:
FC11 G protein-coupled 7TM receptor
- Page 286 and 287:
FC11 G protein-coupled 7TM receptor
- Page 288 and 289:
FC11 G protein-coupled 7TM receptor
- Page 290 and 291:
FC13 Maximising benefits and minimi
- Page 292 and 293:
FC13 Maximising benefits and minimi
- Page 294 and 295:
W29 New horizons in therapeutic dru
- Page 296 and 297:
FC14 Addiction and doping: Neurobio
- Page 298 and 299:
FC15 Endothelium in health and dise
- Page 300 and 301:
FC15 Endothelium in health and dise
- Page 302 and 303:
FC15 Endothelium in health and dise
- Page 304 and 305:
FC16 Natural products: Past and fut
- Page 306 and 307: FC16 Natural products: Past and fut
- Page 308 and 309: FC16 Natural products: Past and fut
- Page 310 and 311: FC16 Natural products: Past and fut
- Page 312 and 313: FC17 New approaches and targets in
- Page 314 and 315: FC18 Nuclear receptor targets for t
- Page 316 and 317: 314 Index Name Paper ref. Name Pape
- Page 318 and 319: 316 Index Name Paper ref. Name Pape
- Page 320 and 321: 318 Index Name Paper ref. Name Pape
- Page 322 and 323: 320 Index Name Paper ref. Name Pape
- Page 324 and 325: 322 Index Name Paper ref. Name Pape
- Page 326 and 327: 324 Index Name Paper ref. Name Pape
- Page 328 and 329: 326 Index Name Paper ref. Name Pape
- Page 330 and 331: 328 Index Name Paper ref. Name Pape
- Page 332 and 333: 330 Index Name Paper ref. Name Pape
- Page 334 and 335: 332 Index Name Paper ref. Name Pape
- Page 336 and 337: 334 Index Name Paper ref. Name Pape
- Page 338 and 339: 336 Index Name Paper ref. Name Pape
- Page 340 and 341: 338 Index Name Paper ref. Name Pape
- Page 342 and 343: 340 Index Name Paper ref. Name Pape
- Page 344 and 345: 342 Index Name Paper ref. Name Pape
- Page 346 and 347: 344 Index Name Paper ref. Name Pape
- Page 348 and 349: 346 Index Name Paper ref. Name Pape
- Page 350 and 351: 348 Index Name Paper ref. Name Pape
- Page 352 and 353: 350 Index Name Paper ref. Name Pape
- Page 354 and 355: 352 Index Name Paper ref. Name Pape
- Page 358 and 359: 356 Index Name Paper ref. Name Pape
- Page 360 and 361: 358 Index Name Paper ref. Name Pape
- Page 362 and 363: 360 Index Name Paper ref. Name Pape
- Page 364 and 365: 362 Index Name Paper ref. Name Pape
- Page 366 and 367: 364 Index Name Paper ref. Name Pape
- Page 368 and 369: 366 Index Name Paper ref. Name Pape
- Page 370 and 371: 368 Index Name Paper ref. Name Pape
- Page 372 and 373: 370 Index Name Paper ref. Name Pape
- Page 374 and 375: 372 Index Name Paper ref. Name Pape
- Page 376 and 377: 374 Index Name Paper ref. Name Pape
- Page 378 and 379: 376 Index Name Paper ref. Name Pape
- Page 380 and 381: 378 Index Name Paper ref. Name Pape
- Page 382 and 383: 380 Index Name Paper ref. Name Pape
- Page 384 and 385: 382 Notes Notes
- Page 386: Final Programme printed in Singapor